Georg Jaeschke
Research Subjects
Georg Jaeschke has a total of 113 co-authors. Here are the top co-authors by number of shared publications:
- Alan G. Hendrick
Storm Therapeutics, Ltd., Moneta Building (B280), Babraham Research Campus, Cambridge CB22 3AT, UK
2 shared publications Antonio Ricci
F. Hoffmann-La Roche Ltd, Roche Pharmaceutical Research and Early Development, Therapeutic Modalities, Roche Innovation Center Basel, Grenzacherstrasse 124, Basel4070, Switzerland
2 shared publicationsBernd Büttelmann
2 shared publicationsDaniel Rueher
F. Hoffmann-La Roche Ltd, Roche Pharmaceutical Research and Early Development, Therapeutic Modalities, Roche Innovation Center Basel, Grenzacherstrasse 124, Basel4070, Switzerland
2 shared publicationsEric Prinssen
2 shared publicationsEric Vieira
2 shared publications
Latest Publications
- 22 October 2026
- Published by American Chemical Society (ACS) in ACS Medicinal Chemistry Letters
- Vol. 17 (11) , 2403-2412
Pyridazino-Indoles as Phenol Bioisosteres for Potent Inhibition of NLRP3
Aberrant activation of the NLRP3 (NACHT, LRR, and PYD domain-containing protein 3) inflammasome drives chronic diseases, necessitating robust therapeutic inhibitors. Despite the promise of phenol-based pyridazines, we sought to evaluate the possibility of replacing the phenol moiety. This article presents the medicinal chemistry efforts leading to the discovery of pyridazino-indoles as potent phenol bioisosteres. These findings are based upon prior work, initially and to the best of our knowledge first disclosed in our Roche patent application published in 2023. Using cryo-EM and molecular modeling, we rationalized the binding mode, ensuring the indole scaffold maintained critical interactions, specifically with Ala228. The resulting lead indole compounds, 13 and 15, achieved single-digit nanomolar potency with excellent solubility, permeability and were profiled in mouse in vivo PK studies. Although hERG inhibition was identified as a safety concern and a reason for discontinuing their development, these novel indoles remain high-quality in vivo tool compounds. We report here the first comprehensive safety audit of the pyridazino-indoles, mapping reactive metabolite pathways.
- 22 October 2026
- Published by American Chemical Society (ACS) in ACS Medicinal Chemistry Letters
- Vol. 17 (11) , 2403-2412
Pyridazino-Indoles as Phenol Bioisosteres for Potent Inhibition of NLRP3
Aberrant activation of the NLRP3 (NACHT, LRR, and PYD domain-containing protein 3) inflammasome drives chronic diseases, necessitating robust therapeutic inhibitors. Despite the promise of phenol-based pyridazines, we sought to evaluate the possibility of replacing the phenol moiety. This article presents the medicinal chemistry efforts leading to the discovery of pyridazino-indoles as potent phenol bioisosteres. These findings are based upon prior work, initially and to the best of our knowledge first disclosed in our Roche patent application published in 2023. Using cryo-EM and molecular modeling, we rationalized the binding mode, ensuring the indole scaffold maintained critical interactions, specifically with Ala228. The resulting lead indole compounds, 13 and 15, achieved single-digit nanomolar potency with excellent solubility, permeability and were profiled in mouse in vivo PK studies. Although hERG inhibition was identified as a safety concern and a reason for discontinuing their development, these novel indoles remain high-quality in vivo tool compounds. We report here the first comprehensive safety audit of the pyridazino-indoles, mapping reactive metabolite pathways.
- 25 November 2024
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 67 (23) , 20911-20932
Novel Macrocyclic NLRP3 Inhibitors
Aberrant activation of NLRP3 due to persistent tissue damage, misfolded proteins or crystal deposits has been linked to multiple chronic inflammatory disorders such as cryopyrin-associated periodic syndrome (CAPS), neurodegenerative diseases, gouty arthritis, and numerous others. Hence, there has been an increasing interest in NLRP3 inhibitors as therapeutics. A first generation of NLRP3 inhibitors bearing a sulfonylurea core such as MCC950 (developed by Pfizer) were discovered by phenotypic screening, however their mode of action was only elucidated later. Based on MCC950, second-generation inhibitors were developed, aiming to overcome some liabilities such as moderate potency and drug induced liver injury. During the optimization of these (second-generation) inhibitors, conformational studies led to the design of novel macrocycles. Here we report the discovery and optimization of this class of NLRP3 inhibitors.
- 25 November 2024
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 67 (23) , 20911-20932
Novel Macrocyclic NLRP3 Inhibitors
Aberrant activation of NLRP3 due to persistent tissue damage, misfolded proteins or crystal deposits has been linked to multiple chronic inflammatory disorders such as cryopyrin-associated periodic syndrome (CAPS), neurodegenerative diseases, gouty arthritis, and numerous others. Hence, there has been an increasing interest in NLRP3 inhibitors as therapeutics. A first generation of NLRP3 inhibitors bearing a sulfonylurea core such as MCC950 (developed by Pfizer) were discovered by phenotypic screening, however their mode of action was only elucidated later. Based on MCC950, second-generation inhibitors were developed, aiming to overcome some liabilities such as moderate potency and drug induced liver injury. During the optimization of these (second-generation) inhibitors, conformational studies led to the design of novel macrocycles. Here we report the discovery and optimization of this class of NLRP3 inhibitors.
- 30 September 2022
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 65 (19) , 13052-13073
Discovery of Novel Allosteric EGFR L858R Inhibitors for the Treatment of Non-Small-Cell Lung Cancer as a Single Agent or in Combination with Osimertinib
Addressing resistance to third-generation EGFR TKIs such as osimertinib via the EGFRC797S mutation remains a highly unmet need in EGFR-driven non-small-cell lung cancer (NSCLC). Herein, we present the discovery of the allosteric EGFR inhibitor 57, a novel fourth-generation inhibitor to overcome EGFRC797S-mediated resistance in patients harboring the activating EGFRL858R mutation. 57 exhibits an improved potency compared to previous allosteric EGFR inhibitors. To our knowledge, 57 is the first allosteric EGFR inhibitor that demonstrates robust tumor regression in a mutant EGFRL858R/C797S tumor model. Additionally, 57 is active in an H1975 EGFRL858R/T790M NSCLC xenograft model and shows superior efficacy in combination with osimertinib compared to the single agents. Our data highlight the potential of 57 as a single agent against EGFRL858R/C797S and EGFRL858R/T790M/C797S and as combination therapy for EGFRL858R- and EGFRL858R/T790M-driven NSCLC.
- 30 September 2022
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 65 (19) , 13052-13073
Discovery of Novel Allosteric EGFR L858R Inhibitors for the Treatment of Non-Small-Cell Lung Cancer as a Single Agent or in Combination with Osimertinib
Addressing resistance to third-generation EGFR TKIs such as osimertinib via the EGFRC797S mutation remains a highly unmet need in EGFR-driven non-small-cell lung cancer (NSCLC). Herein, we present the discovery of the allosteric EGFR inhibitor 57, a novel fourth-generation inhibitor to overcome EGFRC797S-mediated resistance in patients harboring the activating EGFRL858R mutation. 57 exhibits an improved potency compared to previous allosteric EGFR inhibitors. To our knowledge, 57 is the first allosteric EGFR inhibitor that demonstrates robust tumor regression in a mutant EGFRL858R/C797S tumor model. Additionally, 57 is active in an H1975 EGFRL858R/T790M NSCLC xenograft model and shows superior efficacy in combination with osimertinib compared to the single agents. Our data highlight the potential of 57 as a single agent against EGFRL858R/C797S and EGFRL858R/T790M/C797S and as combination therapy for EGFRL858R- and EGFRL858R/T790M-driven NSCLC.
- Open Access
- 9 December 2021
- Published by Swiss Chemical Society in Chimia
- Vol. 75 (12) , 1048-1050
News from the DMCCB - Congress Report from the Virtual EFMC-ISMC 2021
- 9 December 2021
- Published by Swiss Chemical Society in Chimia
- Vol. 75 (12) , 1048-1050
Open AccessNews from the DMCCB - Congress Report from the Virtual EFMC-ISMC 2021
- Open Access
- 19 December 2018
- Published by Swiss Chemical Society in Chimia
- Vol. 72 (12) , 903-904
News from DMCCB – Targeted Protein Degradation
- 19 December 2018
- Published by Swiss Chemical Society in Chimia
- Vol. 72 (12) , 903-904
Open AccessNews from DMCCB – Targeted Protein Degradation
- 2 February 2015
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 58 (3) , 1358-1371
Metabotropic Glutamate Receptor 5 Negative Allosteric Modulators: Discovery of 2-Chloro-4-[1-(4-fluorophenyl)-2,5-dimethyl-1H-imidazol-4-ylethynyl]pyridine (Basimglurant, RO4917523), a Promising Novel Medicine for Psychiatric Diseases
Negative allosteric modulators (NAMs) of metabotropic glutamate receptor 5 (mGlu5) have potential for the treatment of psychiatric diseases including depression, fragile X syndrome (FXS), anxiety, obsessive-compulsive disorders, and levodopa induced dyskinesia in Parkinson’s disease. Herein we report the optimization of a weakly active screening hit 1 to the potent and selective compounds chloro-4-[1-(4-fluorophenyl)-2,5-dimethyl-1H-imidazol-4-ylethynyl]pyridine (basimglurant, 2) and 2-chloro-4-((2,5-dimethyl-1-(4-(trifluoromethoxy)phenyl)-1H-imidazol-4-yl)ethynyl)pyridine (CTEP, 3). Compound 2 is active in a broad range of anxiety tests reaching the same efficacy but at a 10- to 100-fold lower dose compared to diazepam and is characterized by favorable DMPK properties in rat and monkey as well as an excellent preclinical safety profile and is currently in phase II clinical studies for the treatment of depression and fragile X syndrome. Analogue 3 is the first reported mGlu5 NAM with a long half-life in rodents and is therefore an ideal tool compound for chronic studies in mice and rats.
- 2 February 2015
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 58 (3) , 1358-1371
Metabotropic Glutamate Receptor 5 Negative Allosteric Modulators: Discovery of 2-Chloro-4-[1-(4-fluorophenyl)-2,5-dimethyl-1H-imidazol-4-ylethynyl]pyridine (Basimglurant, RO4917523), a Promising Novel Medicine for Psychiatric Diseases
Negative allosteric modulators (NAMs) of metabotropic glutamate receptor 5 (mGlu5) have potential for the treatment of psychiatric diseases including depression, fragile X syndrome (FXS), anxiety, obsessive-compulsive disorders, and levodopa induced dyskinesia in Parkinson’s disease. Herein we report the optimization of a weakly active screening hit 1 to the potent and selective compounds chloro-4-[1-(4-fluorophenyl)-2,5-dimethyl-1H-imidazol-4-ylethynyl]pyridine (basimglurant, 2) and 2-chloro-4-((2,5-dimethyl-1-(4-(trifluoromethoxy)phenyl)-1H-imidazol-4-yl)ethynyl)pyridine (CTEP, 3). Compound 2 is active in a broad range of anxiety tests reaching the same efficacy but at a 10- to 100-fold lower dose compared to diazepam and is characterized by favorable DMPK properties in rat and monkey as well as an excellent preclinical safety profile and is currently in phase II clinical studies for the treatment of depression and fragile X syndrome. Analogue 3 is the first reported mGlu5 NAM with a long half-life in rodents and is therefore an ideal tool compound for chronic studies in mice and rats.
- Open Access
- 1 January 2012
- Published by Springer Nature in Behavioral and Brain Functions
- Vol. 8 (1) , 30
Differential effects of diazepam and MPEP on habituation and neuro-behavioural processes in inbred mice
Previous studies have demonstrated a profound lack of habituation in 129P3 mice compared to the habituating, but initially more anxious, BALB/c mice. The present study investigated whether this non-adaptive phenotype of 129P3 mice is primarily based on anxiety-related characteristics.
- 1 January 2012
- Published by Springer Nature in Behavioral and Brain Functions
- Vol. 8 (1) , 30
Open AccessDifferential effects of diazepam and MPEP on habituation and neuro-behavioural processes in inbred mice
Previous studies have demonstrated a profound lack of habituation in 129P3 mice compared to the habituating, but initially more anxious, BALB/c mice. The present study investigated whether this non-adaptive phenotype of 129P3 mice is primarily based on anxiety-related characteristics.
- 1 March 2007
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 17 (5) , 1307-1311
Synthesis and biological evaluation of fenobam analogs as mGlu5 receptor antagonists
- 1 March 2007
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 17 (5) , 1307-1311
Synthesis and biological evaluation of fenobam analogs as mGlu5 receptor antagonists